Solid oral film dosage forms and methods for making same

• US 9,717,682 B2
• Filed: 01/23/2013
• Issued: 08/01/2017
• Est. Priority Date: 12/08/2009
• Status: Active Grant

• Current Assignee: IntelGenx Corporation
• Original Assignee: IntelGenx Corporation
• Inventors: Zerbe, Horst, Paiement, Nadine, Angusti, Angela, Long, Cormac
• Primary Examiner(s): HUI, SAN MING R
• Application Number:
  US13/748,241
• Publication Number:
  US 20130137698A1
• Time in Patent Office: 1,651 Days
• Field of Search: 514249, 424443
• CPC Class Codes: A61K 31/4985 Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Improved pharmaceutical solid oral film dosage forms for the buccal and/or sublingual delivery of pharmaceutical, nutraceutical or cosmetic ingredients are endowed with instant hydration potential and complete dissolution potentially enabling the active ingredient to become immediately available for enhanced buccal and/or sublingual absorption and/or reduced absorption through the gastrointestinal route. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability by the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix.

Claims

1. An oral film dosage form that maintains a plurality of active ingredient particles in an effective particle size range to maintain reduced structural order, and/or improve solubility and bioavailability of the active, comprising:

at least one pharmaceutically active ingredient in the form of amorphous particles that are capable of existing in crystalline form;

at least one primary crystallization inhibitor present in an amount that inhibits crystallization, growth and agglomeration of the amorphous particles of the pharmaceutically active ingredient;

propylene glycol caprylate in an amount that further enhances inhibition of crystallization, growth and agglomeration of the amorphous particles of the pharmaceutically active ingredient; and

at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.

25. The dosage form of claim 1, in which the amount of the primary crystallization inhibitor is from 25% to 85% of the mass of the film dosage form.

26. The dosage form of claim 25, in which the amount of the liquid crystallization inhibitor is from 1% to 19% of the mass of the film dosage form.

27. The dosage form of claim 26, in which the amount of the plasticizer is from 2% to 25% of the mass of the film dosage form.

2. An oral film dosage form that maintains a plurality of active ingredient particles in an effective particle size range to maintain reduced structural order, and/or improve solubility and bioavailability of the active, comprising:

at least one pharmaceutically active ingredient in the form of amorphous particles having at least two distinct particle size ranges including a first size range of 50-500 nm and a second size range of 100-900 μ

m, the amorphous particles capable of existing in crystalline form;

at least one primary crystallization inhibitor present in an amount that inhibits crystallization, growth and agglomeration of the amorphous particles of the pharmaceutically active ingredient;

at least one liquid crystallization inhibitor in an amount that further enhances inhibition of crystallization, growth and agglomeration of the amorphous particles of the pharmaceutically active ingredient, the at least one liquid crystallization inhibitor selected from propylene glycol caprylate, glyceryl monooleate, and polyethylene glycol; and

at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form, the at least one plasticizer selected from triethyl citrate, tributyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, trioctyl citrate, acetyl trioctyl citrate, trihexyl citrate, dibutyl sebacate, or triacetine, wherein said composition further comprises at least one mucoadhesive polymer.

3. The dosage form of claim 2, wherein said primary crystallization inhibitor is selected from polyvinyl pyrrolidone, polyethylene oxide, or poloxamer.

4. The dosage form of claim 2, wherein said composition further comprises at least one surfactant.

5. The dosage form of claim 2, wherein said composition further comprises at least one penetration enhancer selected from benzalkonium chloride, cetylpyridinium chloride, cyclodextrins, dextran sulfate, lauric acid, propylene glycol, menthol, oleic acid, oleic acid derivatives, polyoxyethylene, polysorbates, sodium EDTA, sodium lauryl sulfate or sodium salicylate.

6. The dosage form of claim 2, wherein said composition further comprises at least one sweetener.

7. The dosage form of claim 2, wherein said composition further comprises at least one colorant.

8. The dosage form of claim 2, wherein said composition further comprises at least one taste masker.

9. The dosage form of claim 2, wherein said composition further comprises at least one antioxidant.

10. The dosage form of claim 2, wherein said composition further comprises at least one flavoring agent.

11. The dosage form of claim 2, wherein said composition further comprises at least one pharmaceutically acceptable excipient.

12. The dosage form of claim 2, wherein said pharmaceutically active ingredient is selected from:

hypnotics, sedatives, antiepileptics, awakening agents, psychoneurotropic agents, neuromuscular blocking agents, antispasmodic agents, antihistaminics, antiallergics, antidiarrhetics, cardiotonics, antiarrhythmics, diuretics, hypotensives, vasopressors, antitussive expectorants, thyroid hormones, sexual hormones, antidiabetics, antitumor agents, antibiotics and chemotherapeutics, and narcotics.

13. An oral film dosage form demonstrating a solubilization profile of at least one active ingredient resulting from the combination of two or more distinct, effectively stabilized, particle size ranges, comprising:

an active ingredient in the form of amorphous particles having at least two distinct particle size ranges including a first size range of 50-500 nm and a second size range of 100-900 μ

m, the amorphous particles capable of existing in crystalline form;

at least one primary crystallization inhibitor present in an amount that inhibits crystallization, growth and agglomeration of the amorphous particles of the pharmaceutically active ingredient;

at least one liquid crystallization inhibitor in an amount that further enhances inhibition of crystallization, growth and agglomeration of the amorphous particles of the pharmaceutically active ingredient the at least one liquid crystallization inhibitor selected from propylene glycol caprylate, glyceryl monooleate, and polyethylene glycol; and

at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form, the at least one plasticizer selected from triethyl citrate, tributyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, trioctyl citrate, acetyl trioctyl citrate, trihexyl citrate, dibutyl sebacate, or triacetine.

14. The dosage form of claim 13, wherein said plasticizer is selected from triethyl, tributyl, acetyl tributyl, acetyl triethyl, trioctyl, acetyl trioctyl, trihexyl citrate, dibutyl sebacate, triacetine, or derivatives thereof.

15. The dosage form of claim 13, wherein said composition further comprises at least one surfactant.

16. The dosage form of claim 13, wherein said composition further comprises at least one penetration enhancer selected from benzalkonium chloride, cetylpyridinium chloride, cyclodextrins, dextran sulfate, laurie acid/propylene glycol, menthol, oleic acid, oleic acid derivatives, polyoxyethylene, polysorbates, sodium EDTA, sodium lauryl sulfate or sodium salicylate.

17. The dosage form of claim 13, wherein said composition further comprises at least one sweetener.

18. The dosage form of claim 13, wherein said composition further comprises at least one colorant.

19. The dosage form of claim 13, wherein said composition further comprises at least one taste masker.

20. The dosage form of claim 13, wherein said composition further comprises at least one antioxidant.

21. The dosage form of claim 13, wherein said composition further comprises at least one flavoring agent.

22. The dosage form of claim 13, wherein said composition further comprises at least one mucoadhesive polymer.

23. The dosage form of claim 13, wherein said composition further comprises at least one pharmaceutically acceptable excipient.

24. The dosage form of claim 13, wherein said pharmaceutically active ingredient is selected from:

hypnotics, sedatives, antiepileptics, awakening agents, psychoneurotropic agents, neuromuscular blocking agents, antispasmodic agents, antihistaminics, antiallergics, antidiarrhetics, card iotonics, antiarrhythmics, diuretics, hypotensives, vasopressors, antitussive expectorants, thyroid hormones, sexual hormones, antidiabetics, antitumor agents, antibiotics and chemotherapeutics, and narcotics.

28. An oral film dosage form that maintains a plurality of active ingredient particles in an effective particle size range to maintain reduced structural order, and/or improve solubility and bioavailability of the active, comprising:

at least one pharmaceutically active ingredient in the form of amorphous particles having at least two distinct particle size ranges including a first size range of 50-500 nm and a second size range of 100-900 μ

m, the amorphous particles capable of existing in crystalline form;

at least one primary crystallization inhibitor present in an amount that inhibits crystallization, growth and agglomeration of the amorphous particles of the pharmaceutically active ingredient;

at least one liquid crystallization inhibitor present in an amount effective to further enhance inhibition of crystallization, growth and agglomeration of the amorphous particles of the pharmaceutically active ingredient, the at least one liquid crystallization inhibitor selected from propylene glycol caprylate, glyceryl monooleate and polyethylene glycol; and

at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form, the at least one plasticizer selected from triethyl citrate, tributyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, trioctyl citrate, acetyl trioctyl citrate, trihexyl citrate, dibutyl sebacate, or triacetine and in which the liquid crystallization inhibitor comprises from 1% to 19% of the mass of the film dosage form.

29. The film of claim 28, wherein the liquid crystallization inhibitor is propylene glycol caprylate.

30. The film of claim 28, wherein the liquid crystallization inhibitor is glyceryl monooleate.